Form 4: Axsome CEO Herriot Tabuteau Receives Performance Stock Units

Axsome Therapeutics CEO Herriot Tabuteau was granted 24,081 performance stock units tied to commercial milestones.

Summary

• CEO Herriot Tabuteau acquired 24,081 performance stock units (PSUs) on April 21, 2026.
• Each PSU represents a contingent right to receive one share of Axsome Therapeutics common stock.
• Vesting of these units is strictly tied to the achievement of specific sales and commercial launch milestones.
• The reporting person must maintain continued service with the company to satisfy vesting requirements.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard executive compensation practices rather than a change in company fundamentals.

Positives

• Alignment of executive compensation with long-term commercial success and sales performance.
• Incentivizes leadership to focus on the successful market launch and adoption of company products.

Negatives

• Potential for future shareholder dilution upon the vesting and conversion of these units into common stock.

Risks

• Failure to achieve the specified sales and commercial launch milestones would result in the forfeiture of these units.
• Continued service requirement creates key-person dependency risk.

Future Outlook

The vesting of the granted units is contingent upon the company achieving specific, undisclosed sales and commercial launch milestones.

Management Comments

• Each PSU will vest upon achievement of certain sales and commercial launch milestones, subject to the reporting person's continued service as of each vesting date.

Industry Context

StockSavvy.ai notes that performance-based equity grants are standard practice in the biotechnology sector to ensure executive incentives are directly linked to the successful commercialization of drug pipelines.

Comparison to Industry Standards

• The use of performance-based vesting criteria is consistent with compensation structures at peer biopharmaceutical companies like Biohaven or Intra-Cellular Therapies.
• Granting equity tied to commercial milestones is a common mechanism to mitigate risk for shareholders during the transition from clinical development to commercial stage.

Stakeholder Impact

• Shareholders may experience minor dilution if milestones are met and shares are issued.
• Employees and creditors benefit from the alignment of executive interests with commercial growth.

Next Steps

• Monitoring of company commercial performance to determine if milestones are met for unit vesting.
• Future SEC filings to track potential conversion of PSUs into common stock.

Key Dates

Keywords

Axsome Therapeutics, AXSM, Herriot Tabuteau, Executive Compensation, Performance Stock Units, Insider Transaction